Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction

Leukemia. 2026 Feb;40(2):449-453. doi: 10.1038/s41375-025-02846-6. Epub 2026 Jan 7.
No abstract available

Publication types

  • Letter